Key result
Clofibrate administered for 6 weeks to patients with type IIa hyperlipoproteinemia decreased platelet sensitivity to ADP and epinephrine, reversing abnormalities linked to increased membrane cholesterol.
Why the study?
Does clofibrate or halofenate improve platelet function abnormalities in hyperbetalipoproteinemia?
Population
Individuals with familial hyperbetalipoproteinemia and normal platelets
Design
Review
Follow-up
6 weeks (for clofibrate)
Authors
Loading...
May normalize platelet reactivity in type IIa hyperlipoproteinemia; hypothesis-generating and should not yet change practice.
Does clofibrate or halofenate improve platelet function abnormalities in hyperbetalipoproteinemia?
Cholesterol enrichment of platelet membranes in hyperbetalipoproteinemia increases membrane microviscosity and platelet hypersensitivity, which can be partially reversed by clofibrate.
Robert W. Colman (1978) conducted a review in Familial hyperbetalipoproteinemia (type IIa hyperlipoproteinemia). Clofibrate and halofenate was evaluated. Clofibrate administered for 6 weeks to patients with type IIa hyperlipoproteinemia decreased platelet sensitivity to ADP and epinephrine, reversing abnormalities linked to increased membrane cholesterol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: